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ABSTRACT
The highest incidence of meningococcal disease
occurs in infants younger than 1 year of age.
However, in the US, prior to June 2012, there
was no meningococcal vaccine licensed for use
in this age group. In the US, where both
serogroups C and Y contribute substantially to
the overall epidemiology of invasive
meningococcal disease, a vaccine combining
these capsular polysaccharides was developed.
We review the newly licensed HibMenCY-TT
(MenHibrixTM, GlaxoSmithKline Biologicals,
Rixensart, Belgium), a novel vaccine
containing Haemophilus influenzae type b (Hib)
and serogroups C and Y Neisseria meningitidis
conjugated to tetanus toxoid. We describe the
vaccine, summarize the clinical trial data, and
describe the patient populations recommended
to receive HibMenCY-TT as their primary
vaccination against Hib. Phase II and III
clinical trials found HibMenCY-TT to be well
tolerated, safe, and immunogenic when
administered at 2, 4, 6, and 12–15 months of
age for primary vaccination against both Hib
and serogroups C and Y meningococcal disease.
In October 2012, the Advisory Committee on
Immunisation Practice in the US recommended
HibMenCY-TT vaccination for infants at
increased risk of meningococcal disease.
HibMenCY-TT may be given concomitantly
with other routine infant vaccines. It induces
antibodies against Hib as well as bactericidal
activity against meningococcal serogroup C
and Y without increasing the number of
injections required. As meningococcal
disease epidemiology is dynamic, global
surveillance remains essential. In the future,
other countries may also benefit from the
addition of HibMenCY-TT into their vaccine
armamentarium against meningococcal disease.
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INTRODUCTION
Neisseria meningitidis (Nm) and Haemophilus
influenzae type b (Hib) are polysaccharide-
encapsulated bacteria capable of rapid invasion
and fulminant disease. Even with readily
available and affordable therapy,
meningococcal disease has a mortality rate of
8–12% and up to 20% of survivors develop
permanent sequelae such as amputations,
hearing loss, and neurodevelopmental
disabilities [1, 2]. Even in the absence of
epidemics, more than 500,000 cases of
invasive meningococcal disease (IMD) occur
annually worldwide of which approximately
50,000 (10%) result in death [3].
Nm is classified based on the chemical
composition of the polysaccharide capsule.
There are 13 antigenically distinct serogroups;
A, B, C, D, E-29, H, I, K, L, W-135, X, Y, and Z, of
which six; A, B, C, W-135, X, and Y, cause
virtually all invasive diseases [4]. The incidence
of IMD may be up to 100 per 100,000 in an
epidemic season in the African meningitis belt
but endemic disease incidence tends to lie
between 1 to 2 per 100,000 in UK, Europe, and
Australia and 0.5 to 1.5 per 100,000 in the US
[5]. The relative contribution of each serogroup
to all IMD is dynamic and varies both
geographically and temporally [5, 6]. The
majority of invasive diseases in Africa are
caused by serogroup A, and in most developed
countries, serogroups B and C. Over the past
decade, serogroup Y has become a major
contributor to IMD in the US and is steadily
increasing in importance in some Nordic
countries [5, 7]. Recently, there also has been a
significant increase in the incidence of
serogroup W-135 in both South Africa and
South America, demonstrating the propensity
for strain dominance to change in
unpredictable ways [8, 9]. The frequency of
IMD also varies by age. The highest burden of
Nm is in young children, especially infants, and
a second smaller peak occurs in adolescence.
The routine use of polysaccharide-protein
conjugate vaccines in infant schedules has
resulted in dramatic country-specific declines
in disease burden and mortality caused by these
encapsulated bacteria [10–12]. Hib, once the
major causative organism of bacterial
meningitis in children under 5 years of age,
has been practically eliminated by routine use
in many countries [13]. The control of IMD,
however, has been more challenging.
In the late 1990s, the emergence of a
hypervirulent meningococcal serogroup C
(MenC) strain prompted the rapid
development and licensure of a monovalent
meningococcal conjugate vaccine. England and
Wales were the first to introduce MenC
conjugate vaccine in their National
Immunization Program (as a three-dose infant
schedule) and simultaneously commenced a
catch-up program for all children and young
adults to 18 years of age (and later 24 years of
age). The program was a great success; MenC
disease fell by 81% in the targeted age group
(\18 years of age) [10]. The vaccine was also
shown to reduce carriage [14], with subsequent
herd protection against disease evidenced by a
67% decrease in attack rate among the
unvaccinated population [15].
Following this success in the UK, and faced
with a similarly increasing burden of serogroup
C meningococcal disease, other European
countries, Australia, and Canada also
incorporated MenC conjugate vaccine into
their National Immunization Programs with
similar success [16, 17]. Today in the post-
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MenC era, the vast majority of ongoing Nm
disease is attributed to serogroup B in these
developed countries [5, 18]. In the UK, between
2006 and 2010 serogroup B accounted for 94%
of Nm disease in children less than 5 years of
age [5]. In Australia in 2011, 91% of Nm disease
in this same age group was due to serogroup B,
with no cases of serogroup C reported [18].
Similar to other regions, the highest
incidence of Nm disease in the US occurs in
infants younger than 12 months of age (5.38
cases per 100,000 population between 1998 and
2007) [19]. However, what differentiates the US
from other countries is the extremely high
contribution of serogroup Y disease to all
cause IMD. Between 1998 and 2007, serogroup
Y was responsible for 34.8% of all
meningococcal isolates (serogroup B, 29.9%,
serogroup C, 28.8% and W-135, 2.5%) [19]. An
efficacious monovalent MenC conjugate
vaccine would combat only one of the three
most prevalent serogroups.
However, the past decade has seen great
advances in quadrivalent meningococcal
conjugate vaccines. In 2005, the first
quadrivalent meningococcal conjugate
vaccine, MenACWY-D (MenactraTM, Sanofi
Pasteur Inc., Swiftwater, PA, USA), containing
Nm serogroup A, C, W-135, and Y
polysaccharides individually conjugated to
diphtheria toxoid, was licensed by the US
Food and Drug Administration (FDA) for use
in persons 11–55 years of age. License
indications have since expanded, and as of
April 2011 include administration as a 2-dose
series in toddlers from 9–23 months of age.
However, MenACWY-D is only poorly
immunogenic in infancy when efficacy against
MenC and Y in the US are needed most [20].
Another quadrivalent meningococcal conjugate
vaccine, MenACWY-CRM197 (Menveo
TM,
Novartis Vaccines, Cambridge, MA, USA),
using C-reactive protein (a mutant of
diphtheria toxoid) as the carrier protein, was
licensed by the US FDA in 2010, and in January
2011 its use was expanded to include children
2–10 years of age. Phase II clinical trials of
MenACWY-CRM197 vaccine in infants have
demonstrated good immunogenicity in this
age group following a 3-dose schedule [21]. A
phase III clinical trial has recently been
completed [22].
In summary, prior to June 2012, there was no
vaccine licensed in the US for the prevention of
meningococcal disease in infants. The
combination of Nm serogroups C and Y
polysaccharides together was specifically
chosen for development to meet a need in the
US for prevention of MenC and MenY IMD in
infants and was manufactured together with
Hib to obviate an additional injection at each
infant vaccination [23].
The Vaccine
HibMenCY-TT is a combination of three
discrete polysaccharide–protein conjugates.
Each 0.5 mL dose of HibMenCY-TT contains
2.5 lg of Hib capsular polysaccharide
(polyribosylribitol phosphate [PRP]) and 5 lg
each of MenC and MenY polysaccharide
individually conjugated or bound to tetanus
toxoid. The total amount of tetanus toxoid is
approximately 17.75 lg. HibMenCY-TT does
not contain adjuvant or preservative.
HibMenCY-TT is supplied as a single-dose
vial of lyophilized vaccine to be
reconstituted with the accompanying vial of
saline diluent [24].
Mechanism of Action
Due to the low incidence of meningococcal
disease, as for other novel meningococcal
Infect Dis Ther (2013) 2:1–13 3
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vaccines, efficacy trials of HibMenCY-TT were
impractical and effectiveness was inferred
based on demonstration of immunogenicity
and achievement of presumed correlates of
protection [25]. Serum bactericidal activity
(SBA) is a functional assay that measures
killing of Nm by antibodies contained in the
patient’s serum in the presence of
complement. The complement source may be
human (hSBA) or rabbit (rSBA). For hSBA, a
titer of C4 is the accepted correlate of
protection for serogroup C based on clinical
effectiveness [26]. For rSBA, a more
conservative titer of C8 has been found to
be most consistent with clinical efficacy of
conjugate vaccines against serogroup C disease
[25, 27]. Of note, this low bactericidal titer
(with rabbit complement) does not necessarily
indicate that bactericidal activity is the
mechanism of immune protection (e.g., it
may be a marker for an alternative
mechanism such as human complement-
enhanced opsonic antibody [28]). For
serogroup Y, no true correlate of protection
exists and the same hSBA and rSBA titers as
for MenC have been accepted as surrogates of
protection [27].
Due to the virtual elimination of Hib disease
through routine vaccination, efficacy trials of
novel Hib vaccines are not feasible.
Effectiveness of the Hib polysaccharide in
HibMenCY-TT was inferred based on
comparative trials with other licensed Hib
vaccines with non-inferiority of
immunogenicity as the end-point. Based on an
efficacy trial with Hib polysaccharide vaccine in
Finland, it has been widely accepted that an
anti-PRP antibody concentration of C0.15 lg/
ml is adequate to confer short-term protection,
and an anti-PRP concentration of C1.0 lg/ml is
required for long-term protection (or protection
for the following 12 months) [29, 30].
CLINICAL TRIAL DATA
Phase II Clinical Trials
There have been six published phase II and III
clinical trials investigating the safety and
immunogenicity of HibMenCY-TT (Table 1)
[31–37]. The initial phase II/dose-finding
comparative studies were performed in
between 2003 and 2004 in Australia [31] and
Belgium and Germany [32]. The Australian
study compared three doses of different
formulations of HibMenCY-TT with licensed
Hib-TT and MenC-CRM in infants at 2, 4, and
6 months of age [31]. The Belgium and German
study compared three doses of different
formulations of HibMenCY-TT with Hib-
MenC-TT or DTap-HepB-IPV/Hib-TT and
MenC-CRM [32] in infants at 2, 3, and
4 months, followed by a booster dose of
HibMenCY-TT at 12–18 months. These phase
II studies showed similar PRP and MenC
seroprotection rates post primary [31, 32] and
post fourth dose [32] and similar safety profiles
after receipt of three or four doses of
HibMenCY-TT compared with licensed control
vaccines. Almost all infants ([97%) developed
functional antibodies (rSBA titer C8) against
MenY [31, 32]. The 2.5/5/5 lg formulation of
HibMenCY-TT, was selected for further clinical
development as it was the least reactogenic and
was the only formulation that did not show any
statistically significant difference in the
proportion of infants with rSBA titer C128
compared with MenC-CRM controls [32].
Two phase II/safety and immunogenicity
studies were performed between 2004 and
2007. A US study compared the Hib immune
response after three doses of HibMenCY-TT
compared with Hib-TT at 2, 4, and 6 months
and compared MenCY immune responses with
that of a toddler control group who received
4 Infect Dis Ther (2013) 2:1–13
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606/366 Immune response of
concomitant antigens given
with HibMenCY-TTa at 2, 4,
6 and 12–15 months of age
Hib-TT DTPa-HBV-
IPV ? PCV7
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MenACWY-PS at 3–5 years of age [33]. A second
phase of this study compared the
immunogenicity and safety of a fourth dose of
HibMenCY-TT compared with Hib-TT in a
subset of infants at 12–15 months who had
previously been primed with three doses of
HibMenCY-TT or Hib-TT, respectively [34]. A
third paper published data from these two
clinical trials on the immune response to
antigens administered concomitantly with
HibMenCY-TT both at priming and at the
fourth booster dose [35]. The US infant study
showed that MenC and Y antibody responses
were higher in infants vaccinated with
HibMenCY-TT than in the control 3- to 5-year-
old children who received a single dose of
MenACWY-PS vaccine [33]. Higher antibody
titers of MenC and Y were also observed post
fourth dose of HibMenCY-TT as compared with
a single dose of HibMenCY at 12–15 months,
providing evidence of immune memory [34].
There was no immune interference to any
concomitantly administered antigens with
HibMenCY-TT in infancy (Streptococcus
pneumoniae serotypes contained in PCV7 or
diphtheria, tetanus, pertussis, hepatitis B, and
poliovirus antigens contained in DTPa-HBV-
IPV) or in anti-pneumococcal antibody
concentrations after the fourth HibMenCY-TT
dose [35].
A large phase II/safety and immunogenicity
study undertaken in Australia randomized
more than 1,100 participants to receive three
doses of HibMenCY-TT at 2, 4, and 6 months
compared with Hib-TT ? MenC-CRM or Hib-TT
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(MMR ? Varivax ? PCV7)
MPSV4 meningococcal ACWY polysaccharide vaccine
a MenHibrixTM, GlaxoSmithKline Biologicals, Rixensart, Belgium
b MenomuneTM, Sanoﬁ Pasteur Inc., Swiftwater, PA, USA
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HibMenCY-TT was given to both the
HibMenCY-TT and MenC-CRM primed
children and Hib-OMP was given to the Hib-
TT primed children. Post third and fourth doses
of HibMenCY-TT, the safety and reactogenicity
profiles were similar and MenC and Hib
antibody responses were noninferior.
However, at 12 months, persistence of MenC
and Hib was better after priming with
HibMenCY-TT compared with children
primed with Hib and MenC monovalent
vaccines [36]. Importantly, this study also
assessed the immunogenicity after two doses
of HibMenCY-TT in infancy and found rSBA
titers C8 against MenC and Y in 94% and 83%,
respectively, suggesting protection from
serogroups C and Y meningococcal disease
may be afforded as early as 5 months of age
with this schedule. However, for all three
HibMenCY antigens a 6-month dose still has
immunologic value suggested by marked rises
in anti-PRP GMC and MenC and Y GMTs after
the third dose [36].
Phase III Clinical Trials
The phase III/pivotal clinical trial evaluated the
safety, immunogenicity, and lot-to-lot
consistency of HibMenCY-TT in 4,180 infants
in three cohorts, across 91 centers in three
countries [37]. Cohort one included only US
infants for immunogenicity and safety
(n = 991), cohort two included children in the
US, Australia, and Mexico for safety endpoints
only (n = 2,989), and cohort three, Mexican
infants for immunogenicity and safety
(n = 200). As there was no licensed MenC
vaccine available to use as a control in this age
group in the US, all infants were randomized to
receive three doses of HibMenCY-TT or Hib-TT
at 2, 4, and 6 months and HibMenCY-TT or Hib-
OMP at 12–15 months (monovalent MenC was
administered to Australian children after the
study completion in accordance with their
National Immunisation Program) [37].
Immunogenicity Against Nm Serogroups
C and Y
The proportion of participants with hSBA titers
C8 was 99% and 96% after the third dose and
99% after dose 4, for both MenC and MenY,
respectively. MenC and Y hSBA titers increased
12-fold from pre- to post-fourth dose levels [37].
Immunogenicity Against Hib
The proportion of participants with anti-PRP
antibody concentrations C1.0 lg/ml was
noninferior (96% in the HibMenCY-TT group
vs. 91% the Hib-TT group post dose 3 and 99%
post dose 4 for both HibMenCY-TT and control
Hib-OMP groups) [37]. As in phase II studies,
PRP GMCs were significantly higher after three
doses of HibMenCY-TT than Hib-TT [33, 36, 37]
and also pre-dose 4 and 1 month after the
fourth dose compared with after monovalent
Hib vaccine [34, 36, 37]. Further, a booster
response to the fourth dose of HibMenCY-TT
was observed [34, 36].
Concomitant Vaccine Administration
Co-administration of HibMenCY-TT with DTPa-
HBV-IPV and PVC7 at 2, 4, and 6 months did
not cause immune interference to any
concomitantly administered antigens [35].
Further, a pooled analysis of 1,257 toddlers
found non inferiority of immune responses to
measles, mumps and rubella, and varicella
antigens when administered concomitantly
with a fourth dose of HibMenCY-TT compared
to Hib-OMP vaccine at 12–15 months of age
[38].
Infect Dis Ther (2013) 2:1–13 7
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Safety and Tolerability
Despite the addition of MenC and Y antigens,
the reactogenicity of HibMenCY-TT does not
differ from that associated with administration
of Hib-TT vaccine [33, 36, 37]. A pooled safety
analysis that included more than 8,500
participants from two primary vaccination
and two-fourth dose phase III clinical trials
found the incidence of serious adverse events,
adverse events and solicited local and general
systemic symptoms were similar following
HibMenCY-TT and licensed Hib vaccines [39].
Rates of pain at the injection site and
irritability were significantly lower following





On June 14, 2012, HibMenCY-TT became the
first meningococcal vaccine licensed by the FDA
for use in infants, age 2–8 months in the US. It
was approved for use in children age 6 weeks to
18 months for the prevention of invasive Hib
and serogroup C and Y meningococcal disease
[24].
Recommendations for Use
Phase II and III clinical trials have found
HibMenCY-TT vaccine to be well tolerated,
safe, and immunogenic in infants for primary
vaccination against both Hib and serogroups C
and Y meningococcal disease. Routine use in
the US would prevent a substantial proportion
of IMD in infants without increasing the
number of injections required at each
vaccination visit.
However, in October 2012, rather than
recommending universal Nm serogroup C and
Y infant vaccination, the ACIP voted to
recommend vaccination only for infants at
increased risk of meningococcal disease [40].
The ACIP primarily based its recommendations
on the current epidemiology of meningococcal
disease in the US, which is at an historic low.
The incidence of Nm in the US has been
decreasing since 2000 and was only 0.21 cases
per 100,000 population in 2011. Whilst young
children (\5 years of age) still accounted for
the highest age incidence of disease between
1993 and 2007 in the US (1.74 per 100,000
population), approximately 60% of disease in
that age group was caused by serogroup B.
Further, the highest incidence in children aged
less than 5 years is in those in the first
6 months of life when most infants would
still be too young to have received two or
three doses of vaccine required for adequate
protection [40]. Cost-effectiveness estimates are
unfavorable. In October 2011, the CDC
calculated the cost per quality-adjusted life
year (QALY) averted for infant meningococcal
vaccination in the US to be $3.6 million per
case [41]. Accordingly, the ACIP concluded that
the present low burden of disease, combined
with the lack of efficacy of conjugate
meningococcal vaccines against serogroup B,
limits the potential impact of a routine infant
meningococcal program in the US [40]. While
the report did not raise the issues of
programmatic implications, routine use of
HibMenCY-TT would preclude many other
Hib combination vaccines presently licensed
for use in the infant schedule.
Recommended Schedule
HibMenCY-TT is recommended for use in
infants as a 4-dose series (3 primary doses and
8 Infect Dis Ther (2013) 2:1–13
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a single booster), each 0.5 mL dose given by
intramuscular injection at 2, 4, 6, and
12–15 months of age. The first dose may be
given as early as 6 weeks. The fourth dose may
be given as late as 18 months of age [24].
The ACIP has recommended HibMenCY-TT
be used in infants at increased risk of
meningococcal disease, including those with
persistent complement component pathway
deficiencies or functional or anatomical
asplenia. Additionally, some infants with
complex congenital heart disease may have
asplenia and infants recognized with sickle cell
disease through newborn screening warrant
vaccination as they often develop functional
asplenia during early childhood. HibMenCY-TT
vaccination of healthy infants (6 weeks to
18 months) may also be infrequently
recommended, e.g., during a community or
organization outbreak of MenC or MenY
disease. Finally, despite not receiving ACIP
recommendation for universal use,
HibMenCY-TT may still be used in the US (for
those who can afford to pay) in any infant for
routine vaccination against Hib and at the same
time affording some protection against
serogroups C and Y meningococcal disease
(Table 2) [40, 42].
Children recognized in early infancy as being
at increased risk for meningococcal disease
should receive a four-dose series as outlined
above. The ACIP recommends the following
alternative schedules for use in the following
circumstances [40]: If an infant at risk of
meningococcal disease falls behind in their
Hib vaccine doses, HibMenCY-TT may be
given as per the recommended Hib catch-up
schedule. If, however, the first dose of
HibMenCY-TT is given after 12 months of age,
two doses should be given at least 8 weeks apart
to ensure adequate protection against Nm
serogroups C and Y. For infants at risk of
meningococcal disease who have received or
are going to receive a different Hib vaccine
product, they should receive MenACWY-D if
they are between 9–23 months of age or
MenACWY-CRM or MenACWY-D from
24 months of age.
HibMenCY-TT may be given concomitantly
with other routine infant vaccines, including 7-
or 13-valent pneumococcal conjugate vaccines
[33, 35, 37, 40]. It may also be given
concomitantly with MMR and varicella
vaccine [37]. As HibMenCY-TT incudes Hib, it
should not be administered concomitantly with
other Hib-containing vaccines.
It is important to note that HibMenCY-TT
affords no protection against serogroups A, B, or
W-135 meningococcal disease. For infants
traveling to the Hajj or to the ‘meningitis belt’
of sub-Saharan Africa, who need protection
against MenA and MenW-135, a quadrivalent
meningococcal conjugate vaccine may be
offered (MenACWY-D is currently licensed
for children C9 months of age in the US).
There is currently no licensed quadrivalent
meningococcal vaccine for infants under
9 months of age. Earlier this year, a non-strain
specific meningococcal vaccine against
serogroup B disease was licensed in Europe
(BexseroTM, Novartis Vaccines, Cambridge,
MA, USA) [43].
As meningococcal disease epidemiology is
dynamic, global surveillance of capsular
switching and serogroup replacement will
remain essential. If the increase in serogroup
Y disease in some European countries
continues, re-evaluation of meningococcal C
vaccine strategies will be necessary that may
warrant expansion of coverage to include C
and Y. Quadrivalent MenACWY-CRM vaccine
and possibly MenACWY-TT are also likely to be
available for use in infants in the future adding
to choice, but at present add marginal benefit
Infect Dis Ther (2013) 2:1–13 9
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to the monovalent MenC or bivalent MenCY
vaccine in most developed countries given low
levels of serogroup A and W-135 disease.
Ultimately, global control of IMD will require
the addition of broad strain coverage serogroup
B vaccines, although the effectiveness of the
first of these vaccines remains to be
determined.
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Table 2 Eligible groups of children (2–18 months old) for meningococcal vaccination
Subgroup Primary vaccination (age of
vaccination)
Booster dose
Complement deﬁciencies HibMenCY-TTa (four doses at 2, 4,




2 doses 3 months apart)
If ﬁrst dose received at age 9 months
to 6 years and remain at increased
risk for meningococcal disease,
should receive an additional dose of
MCV4 (MenACWY-Db or
MenACWY-CRM197
c ) 3 years after
primary vaccination. Boosters




HibMenCY-TTa (four doses at 2, 4,




2 doses 3 months apart)
Part of a community or
organization outbreak
HibMenCY-TTa (four doses at 2, 4,




2 doses 3 months apart)
Traveling to the Hajj or
the ‘meningitis belt’
MenACWY-Db (9–18 months,
2 doses 3 months apart)
Adapted from the Center for Disease Control and Prevention’s Advisory Committee on Immunization Practices
recommendations. Vaccines for children program. Vaccines to prevent meningococcal disease. 2012. Available at:
http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/1012-2-mening-mcv.pdf
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